FDA Inspection 1328662 — GAMBRO DASCO SPA BLOOD LINE DIVISION
The FDA completed an inspection of GAMBRO DASCO SPA BLOOD LINE DIVISION on Jul 16, 2026 in Medolla. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Devices.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jul 16, 2026
- Fiscal Year
- 2026
- Product Type
- Devices
- Project Area
- Compliance: Devices
- Location
- Medolla (Italy)